We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Draft Version of the Neanderthal Genome Completed

By LabMedica International staff writers
Posted on 11 Mar 2009
Scientists have just completed a first draft version of the Neanderthal genome.

The Max Planck Institute for Evolutionary Anthropology (Leipzig, Germany) and the 454 Life Sciences Corp. More...
(Branford, CT, USA) presented their findings February 12, 2009, during the 2009 annual meeting of the American Association for the Advancement of Science (AAAS), in Chicago, IL, USA, and at a simultaneous European press briefing.

The project is directed by Prof. Svante Pääbo, director of the Institute's department of evolutionary genetics anthropology. The professor and his colleagues have sequenced more than one billion DNA fragments extracted from three Croatian Neanderthal fossils, using innovative techniques developed for this project. The Neanderthal genome sequence will clarify the evolutionary relationship between humans and Neanderthals as well as help identify those genetic changes that enabled modern humans to leave Africa and rapidly spread around the world, starting approximately 100,000 years ago.

Neanderthals (sp. Homo neanderthalensis) were the closest relatives of currently living humans. They lived in Europe and parts of Asia until they became extinct approximately 30,000 years ago. For more than 100 years, paleontologists and anthropologists have been trying to uncover their evolutionary relationship to modern humans. Prof. Pääbo, a pioneer in the field of ancient DNA research, made the first contribution to the understanding of our genetic relationship to Neanderthals when he sequenced Neanderthal mitochondrial DNA in 1997. Together with the company 454 Life Sciences, Prof. Pääbo has now reported on a new milestone in Neanderthal research. The two groups have sequenced a total of more than 3 billion bases of Neanderthal DNA, generating a first draft sequence of the entire Neanderthal genome. Altogether, these fragments comprise more than 60% of the entire Neanderthal genome. These DNA sequences can now be compared to the earlier sequenced human and chimpanzee genomes in order to arrive at some initial insights into how the genome of this extinct form differed from that of modern humans.

In 2006, Prof. Pääbo's group published papers together with 454 Life Sciences that showed that it was possible to use the 454 technology to determine large amounts of nuclear DNA sequences from late Pleistocene animals such as mammoths as well as the Neanderthal. Building on these findings, Prof. Pääbo and Dr. Michael Egholm, vice president of Research and Technology of 454 Life Sciences, initiated an ambitious project to sequence the Neanderthal genome. Together, the groups have overcome a number of technical obstacles in order to arrive at this first view of the entire genome of an extinct form of human.

One key element developed by Dr. Pääbo's group was the production of sequencing libraries under "clean-room” conditions to avoid contamination of experiments by human DNA. They also designed DNA sequence tags that carry unique identifiers and are attached to the ancient DNA molecules in the clean room. This makes it possible to avoid contamination from other sources of DNA during the sequencing procedure, which was a hurdle in the initial proof-of-principle experiments in 2006. They also used minute amounts of radioactively labeled DNA to identify and modify those steps in the sequencing procedure where losses occur. Together with other developments implemented during the project, these innovations drastically reduced the need for precious fossil material so that less than half a gram of bone was used to produce the draft sequence of three billion base pairs.

In order to effectively compare the Neanderthal DNA sequences to those of humans and chimpanzees, the Leipzig research group has performed detailed studies of where chemical damage tends to occur in the ancient DNA and how it causes errors in the DNA sequences. The researchers found that such errors occur most frequently towards the ends of molecules and that most of them are due to a specific modification of one of the bases in the DNA that occurs over time in fossil remains. They then applied this knowledge to identify which of the DNA fragments from the fossils come from the Neanderthal genome and which from microorganisms that have colonized the bones during the thousands of years they lay buried in the caves. They have also developed novel and more sensitive computer algorithms to put the Neanderthal DNA fragments in order and compare them to the human genome.

In total, the group has determined over 100 million DNA sequence fragments from fossils by the 454 technology and over a billion DNA sequences with the Solexa technology, another sequencing technology that is particularly efficient in reading many short sequences. The majority of the sequence comes from Neanderthal bones from Vindija Cave in Croatia, which the group studies as a part of a long-term collaboration between the Croatian Academy of Sciences and Arts (Zagreb) and the Berlin-Brandenburg (Germany) Academy. To assess if the findings from this Neanderthal are typical of those of other Neanderthals, the researchers have also sequenced several million base pairs from Neanderthals from other sites.

Prof. Javier Fortea and colleagues from Oviedo, Spain, have excavated 43,000-year-old Neanderthal bones under sterile conditions at El Sidron, Spain, that have yielded DNA sequences, while Dr. Lubov Golovanova and Dr. Vladimir Doronichev from St. Petersburg, Russia, have contributed a 60-70,000-year-old bone from Mezmaiskaya Cave in the Caucasus. Moreover, Dr. Ralf Schmitz from the LVR-Landesmuseum in Bonn, Germany has allowed a sample to be removed from the 40,000-year-old Neanderthal type specimen, which was found in 1856 in the Neander Valley, the origin of the name, Neanderthal. This will allow important findings from the Croatian Neanderthal to be verified in several Neanderthals including the specimen that defines the Neanderthals as a distinct group.

In order to aid in the analysis of the Neanderthal genome, Prof. Pääbo has organized a consortium of researchers worldwide that plans to publish their results later in 2009. They will look at many genes of special interest in recent human evolution, such as FOXP2, which is involved in speech and language in modern humans, as well as genes such as the Tau locus and the microcephalin-1, implicated in brain aging and development, respectively. Variants of the latter genes found among present-day humans have been suggested to come from Neanderthals. The preliminary results suggest that Neanderthals have contributed, at most, a very small fraction of the variation found in contemporary human populations.

Related Links:

Max Planck Institute for Evolutionary Anthropology
454 Life Sciences



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.